H.C. Wainwright Reiterates Buy Rating on Sangamo BioSciences (SGMO)

H.C. Wainwright analyst Patrick R. Trucchio reiterated a Buy rating and $10.00 price target on Sangamo BioSciences (NASDAQ: SGMO).

The analyst commented: "This morning, Sangamo announced top-line results from the Phase 1/2 STAAR trial evaluating isaralgagene civaparvovec (ST-920 or isa-vec), an adeno-associated virus (AAV2/6)-based alpha-galactosidase A (α-Gal A) gene therapy in adults with Fabry disease. Overall, we continue to view isa-vec as a potential best-in-class, one-time gene therapy for Fabry disease, supported by long-term α-Gal A expression, enzyme replacement therapy (ERT) discontinuation, renal function stabilization, and improvements in quality of life. Based on these positive data, Sangamo is preparing a Biologics License Application (BLA) for potential submission as early as 1Q26, which would support a commercial launch for the potential first-in-class gene therapy in 2H26. Importantly, we believe the STAAR data may accelerate the timeline to a potential partnership agreement, in our view. We reiterate our Buy rating and $10 price target on SGMO."

For an analyst ratings summary and ratings history on Sangamo BioSciences click here. For more ratings news on Sangamo BioSciences click here.

Shares of Sangamo BioSciences closed at $0.51 yesterday.

You May Also Be Interested In

• Sangamo picks Lilly and PTC as buyers in bankruptcy auction
• Mannatech (MTEX) Tops Q2 EPS by 53c
• Nortech Systems, Inc. (NSYS) Tops Q2 EPS by 11c